| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Arkansas Epilepsy Program (Dr. Biton), Little Rock; Neurology and Epileptology (Dr. Mirza), Bridgeton, and Comprehensive Epilepsy Care Center (Dr. Montouris), St. Louis, MO; and Glaxo Wellcome (Dr. Barrett, A. Vuong, and A.E. Hammer), Research Triangle Park, NC.
Address correspondence and reprint requests to Dr. V. Biton, Arkansas Epilepsy Program, One Lile Court, Suite 100, Little Rock, AR 72205.
OBJECTIVE: To compare the incidence and magnitude of change in body weight associated with lamotrigine or divalproex sodium monotherapy in patients with epilepsy.
METHODS: A randomized, double-blind study with 8-week escalation phase and 24-week maintenance phase was conducted. Target maintenance dosage was 200 mg/day (lamotrigine) and 20 mg/kg/day (valproic acid), with adjustment from 100 to 500 mg/day (lamotrigine) and 10 to 60 mg/kg/day (valproate) based on investigators’ judgment. Eligible patients were 
12 years old with new-onset or previously diagnosed partial or generalized seizures. Weight change was primary and seizure frequency and tolerance were secondary outcome measures.
RESULTS: For the lamotrigine group, 65 patients (mean age 34.5 years) were investigated; for the valproate group, 68 patients (mean age 30.1 years) were investigated. Weight remained stable in lamotrigine-treated patients. Significant weight gain occurred in valproate-treated patients by the 10th week of treatment; weight continued to increase throughout the study. After 32 weeks of treatment, mean weight gain was significantly higher in valproate-treated (12.8 ± 9.3 lb) than lamotrigine-treated (1.3 ± 11.9 lb) patients. Similar proportions of patients in lamotrigine (29%) and valproate (26%) groups were seizure-free. Overall frequency of adverse events was similar between the two treatment groups. Mean time to withdrawal from the study due to adverse events was 103 ± 70 days for the lamotrigine group and 79 ± 48 days for the valproate group.
CONCLUSION: Valproate monotherapy was associated with significantly greater weight gain than lamotrigine monotherapy. Weight gain associated with valproate was significant within 10 weeks after initiating therapy and continued throughout the study. Efficacy of lamotrigine was comparable with that of valproate; lamotrigine tended to be better tolerated.
This article has been cited by other articles:
|
|
 |
|
  S. Gungor, G. Yucel, A. Akinci, Y. Tabel, I. H. Ozerol, and S. Yologlu The Role of Ghrelin in Weight Gain and Growth in Epileptic Children Using Valproate J Child Neurol, December 1, 2007; 22(12): 1384 - 1388. [Abstract] [PDF]
|
|
|
|
 |
|
 W.S. Leslie, C.R. Hankey, and M.E.J. Lean Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review QJM, July 1, 2007; 100(7): 395 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Steinhoff Optimizing therapy of seizures in patients with endocrine disorders Neurology, December 26, 2006; 67(12_suppl_4): S23 - S27. [Abstract] [Full Text]
|
|
|
|
|
|
J. R. McKee, T. R. Sunder, A. Vuong, and A. E. Hammer Adjunctive Lamotrigine for Refractory Epilepsy in Adolescents with Mental Retardation J Child Neurol, May 1, 2006; 21(5): 372 - 379. [Abstract] [PDF]
|
|
|
|
|
|
R. D. Sheth and B. E. Gidal Topical Review: Optimizing Epilepsy Management in Teenagers J Child Neurol, April 1, 2006; 21(4): 273 - 279. [Abstract] [PDF]
|
|
|
|
|
|
K. Aydin, A. Serdaroglu, C. Okuyaz, A. Bideci, and K. Gucuyener Serum Insulin, Leptin, and Neuropeptide Y Levels in Epileptic Children Treated With Valproate J Child Neurol, October 1, 2005; 20(10): 848 - 851. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Hawkins, D. Epstein, M. Drummond, J. Wilby, A. Kainth, D. Chadwick, and M. Sculpher Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model Med Decis Making, September 1, 2005; 25(5): 493 - 510. [Abstract] [PDF]
|
|
|
|
 |
|
 D. C. Lagace, R. S. McLeod, and M. W. Nachtigal Valproic Acid Inhibits Leptin Secretion and Reduces Leptin Messenger Ribonucleic Acid Levels in Adipocytes Endocrinology, December 1, 2004; 145(12): 5493 - 5503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Kaplan Reproductive health effects and teratogenicity of antiepileptic drugs Neurology, November 23, 2004; 63(10_suppl_4): S13 - S23. [Abstract] [Full Text]
|
|
|
|
|
|
R. D. Sheth Metabolic concerns associated with antiepileptic medications Neurology, November 23, 2004; 63(10_suppl_4): S24 - S29. [Abstract] [Full Text]
|
|
|
|
 |
|
 S Beyenburg, J Bauer, and M Reuber New drugs for the treatment of epilepsy: a practical approach Postgrad. Med. J., October 1, 2004; 80(948): 581 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mikkonen, L. K. Vainionpaa, A. J. Pakarinen, M. Knip, I. Y. Jarvela, J. S. Tapanainen, and J. I. Isojarvi Long-term reproductive endocrine health in young women with epilepsy during puberty Neurology, February 10, 2004; 62(3): 445 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Nicolson, R E Appleton, D W Chadwick, and D F Smith The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies J. Neurol. Neurosurg. Psychiatry, January 1, 2004; 75(1): 75 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. T. Isojarvi Reproductive dysfunction in women with epilepsy Neurology, September 1, 2003; 61(90062): S27 - 34. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Tohen, T. A. Ketter, C. A. Zarate, T. Suppes, M. Frye, L. Altshuler, J. Zajecka, L. M. Schuh, R. C. Risser, E. Brown, et al. Olanzapine Versus Divalproex Sodium for the Treatment of Acute Mania and Maintenance of Remission: A 47-Week Study Am J Psychiatry, July 1, 2003; 160(7): 1263 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Weigle Pharmacological Therapy of Obesity: Past, Present, and Future J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2462 - 2469. [Full Text] [PDF]
|
|
|
|
|
|
V. Pylvanen, M. Knip, A. J. Pakarinen, J. Turkka, M. Kotila, J. Rattya, V. V. Myllyla, and J. I.T. Isojarvi Fasting serum insulin and lipid levels in men with epilepsy Neurology, February 25, 2003; 60(4): 571 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Biton, P. Levisohn, S. Hoyler, A. Vuong, and A. E. Hammer Lamotrigine Versus Valproate Monotherapy--Associated Weight Change in Adolescents With Epilepsy: Results From a Post Hoc Analysis of a Randomized, Double-Blind Clinical Trial J Child Neurol, February 1, 2003; 18(2): 133 - 139. [Abstract] [PDF]
|
|
|
|
|
|
J Bauer, J I T Isojarvi, A G Herzog, M Reuber, D Polson, E Tauboll, P Genton, H van der Ven, B Roesing, G J Luef, et al. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management J. Neurol. Neurosurg. Psychiatry, August 1, 2002; 73(2): 121 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Sheth Adolescent Issues in Epilepsy J Child Neurol, February 1, 2002; 17(2_suppl): 2S23 - 2S27. [Abstract] [PDF]
|
|
|
|
|
|
J. Messenheimer Efficacy and Safety of Lamotrigine in Pediatric Patients J Child Neurol, February 1, 2002; 17(2_suppl): 2S34 - 2S42. [Abstract] [PDF]
|
|
|
|
|
|
G. Luef, I. Abraham, E. Trinka, I. Unterberger, F. Hoppichler, G. Bauer, M. Lechleitner, and V. Biton Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy Neurology, August 14, 2001; 57(3): 565 - 566. [Full Text]
|
|
|
|
 |
|
 Weight Gain in Epilepsy: Valproate vs. Lamotrigine Monotherapy Journal Watch Psychiatry, July 26, 2001; 2001(726): 14 - 14. [Full Text]
|
|
|
|
 |
|
 Weight Gain in Epilepsy: Valproate vs. Lamotrigine Monotherapy Journal Watch Neurology, May 10, 2001; 2001(510): 6 - 6. [Full Text]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
